WBZ-TV's Dr. Mallika Marshall reports that drug maker Eli Lilly put its own weight loss drug Zepbound against the popular ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

Donald Trump has launched a new war, this time against pharmaceutical companies. He has signed an executive order to reduce ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales.

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has already been approved in the US, China ... Orexigen's weight-loss therapy ...

Field noted, however, that although U.S. consumers typically pay more for branded drugs, the picture is far from clear ... such as weight loss drug makers Novo Nordisk and Eli Lilly.

Mazdutide – a once-weekly injectable Innovent licensed from Lilly – was submitted to ... including weight loss and cardiometabolic benefits, compared to the control drug.